Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes

Medical Oncology

Volumn 33, Issue 11, 2016, Pages

  Nitta, Hidetoshi ^a   Shimose, Takayuki ^b   Emi, Yasunori ^c   Imamura, Takahisa ^a   Ohnishi, Koji ^a   Kusumoto, Tetsuya ^d   Yamamoto, Manabu ^e   Fukuzawa, Kengo ^f   Takahashi, Ikuo ^g   Higashi, Hidefumi ^h   Tsuji, Akihito ⁱ   Akagi, Yoshito ^j   Oki, Eiji ^k   Maehara, Yoshihiko ^k   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Clinical Research Support Center Kyushu   (Japan)

^c SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^e NATIONAL KYUSHU CANCER CENTER   (Japan)

^f OITA RED CROSS HOSPITAL   (Japan)

^g MATSUYAMA RED CROSS HOSPITAL   (Japan)

^h STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

ⁱ KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^j KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k KYUSHU UNIVERSITY   (Japan)

^l KSCC) ancillary study

more..

Author keywords

C5a; C5a receptor; Gastric cancer; Invasion; Liver metastasis

Indexed keywords

COMPLEMENT COMPONENT C5A RECEPTOR;

AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; FEMALE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LYMPHATIC INVASION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; STOMACH CANCER; TUMOR INVASION; VASCULAR INVASION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LIVER TUMOR; METABOLISM; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SECONDARY; STOMACH TUMOR; TUMOR RECURRENCE;

AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ANAPHYLATOXIN C5A; STOMACH NEOPLASMS;

EID: 84989359850     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-016-0834-9     Document Type: Article

References (41)

1. Roder DM. The epidemiology of gastric cancer. Gastric Cancer. 2002;5(suppl 1):5–11.
2. Kakushima N, Fujishiro M. Endoscopic submucosal dissection for gastrointestinal neoplasms. World J Gastroenterol. 2008;14:2962–7.
3. Gotoda T, Iwasaki M, Kusano C, Seewald S, Oda I. Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg. 2010;97:868–71.
4. Kitano S, Shiraishi N. Current status of laparoscopic gastrectomy for cancer in Japan. Surg Endosc. 2004;18:182–5.
5. Sun Z, Nussbaum DP, Speicher PJ, Czito BG, Tyler DS, Blazer DG 3rd. Neoadjuvant radiation therapy does not increase perioperative morbidity among patients undergoing gastrectomy for gastric cancer. J Surg Oncol. 2015;112:46–50.
6. Zhang YJ, Fang JY. Molecular staging of gastric cancer. J Gastroenterol Hepatol. 2008;23:856–60.
7. Katoh M. Epithelial-mesenchymal transition in gastric cancer (review). Int J Oncol. 2005;27:1677–83.
8. Wang J, Wang Q, Liu H, Hu B, Zhou W, Cheng Y. MicroRNA expression and its implication for the diagnosis and therapeutic strategies of gastric cancer. Cancer Lett. 2010;297:137–43.
9. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol. 2004;5:981–6.
10. Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature. 1991;349:614–7.
11. Smedly LA, Tonnesen MG, Sandhaus RA, Haslett C, Guthrie LA, Johnston RB Jr, et al. Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest. 1986;77:1233–43.
12. Grant JA, Settle L, Whorton EB, Dupree E. Complement-mediated release of histamine from human basophils. II. Biochemical characterization of the reaction. J Immunol. 1976;117:450–6.
13. Nitta H, Wada Y, Kawano Y, Murakami Y, Irie A, Taniguchi K, et al. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a-receptor (CD88). Clin Caner Res. 2013;19:2004–13.
14. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, et al. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9:1225–35.
15. Niculescu F, Rus HG, Retegan M, Vlaicu R. Persistent complement activation on tumor cells in breast cancer. Am J Pathol. 1992;140:1039–43.
16. Oki E, Tokunaga S, Emi Y, Kusumoto T, Yamamoto M, Fukuzawa K, et al. Kyushu Study Group of Clinical Cancer. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer. 2016;19:968–76.
17. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.
18. Fayyazi A, Scheel O, Werfel T, Schweyer S, Oppermann M, Götze O, et al. The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells. Immunology. 2000;99:38–45.
19. Wu X, Yang Y, Xu Z, Li J, Yang B, Feng N, et al. Raf kinase inhibitor protein mediated signaling inhibits invasion and metastasis of hepatocellular carcinoma. Biochim Biophys Acta. 2016;1860:384–91.
20. Chia CS, Ban K, Ithnin H, Singh H, Krishnan R, Mokhtar S, et al. Expression of interleukin-18, interferon-γ and interleukin-10 in hepatocellular carcinoma. Immunol Lett. 2002;84:163–72.
21. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540–50.
22. Laudes IJ, Chu JC, Huber-Lanq M, Guo RF, Riedemann NC, Sarma JV, et al. Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol. 2002;169:5962–70.
23. Schraufstatter IU, Trieu K, Sikora L, Sriramarao P, DiScipio R. Complement C3a and C5a induce different signal transduction cascades in endothelial cells. J Immunol. 2002;169:2102–10.
24. Shushakova N, Tkachuk N, Dangers M, Tkachuk S, Park JK, Hashimoto K, et al. Urokinase-induced activation of the gp130/Tyk2/Stat3 pathway mediates a pro-inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor. J Cell Sci. 2005;118:2743–53.
25. Riedemann NC, Guo RF, Sarma VJ, Laudes IJ, Huber-Lang M, Warner RL, et al. Expression and function of the C5a receptor in rat alveolar epithelial cells. J Immunol. 2002;168:1919–25.
26. Allen-Gipson DS, Floreani AA, Heires AJ, Sanderson SD, MacDonald RG, Wyatt TA. Cigarette smoke extract increases C5a receptor expression in human bronchial epithelial cells. J Pharmacol Exp Ther. 2005;314:476–82.
27. Cai K, Wan Y, Wang Z, Wang Y, Zhao X, Bao X. C5a promotes the proliferation of human nasopharyngeal carcinoma cells through PCAF-mediated STAT3 acetylation. Oncol Rep. 2014;32:2260–6.
28. Maeda Y, Kawano Y, Wada Y, Yatsuda J, Motoshima T, Murakami Y, et al. C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways. Oncol Rep. 2015;33:1844–50.
29. Gu J, Ding JY, Lu CL, Lin ZW, Chu YW, Zhao GY, et al. Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer. Lung Cancer. 2013;81:259–65.
30. Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, et al. Autocrine effects of tumor-derived complement. Cell Rep. 2014;6:1085–95.
31. Imamura T, Yamamoto-Ibusuki M, Sueta A, Kubo T, Irie A, Kikuchi K, et al. Influence of the C5a–C5a receptor system on breast cancer progression and patient prognosis. Breast Cancer. 2015. doi:10.1007/s12282-015-0654-3.
32. Wada Y, Maeda Y, Kubo T, Kikuchi K, Eto M, Imamura T. C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy. Oncol Lett. 2016. doi: 10.3892/ol.2016.5137.
33. Burg M, Martin U, Rheinheimer C, Köhl J, Bautsch W, Böttger EC, et al. IFN-gamma up-regulates the human C5a receptor (CD88) in myeloblastic U937 cells and related cell lines. J Immunol. 1995;155:4419–26.
34. Schlaf G, Schmitz M, Rothermel E, Jungermann K, Schieferdecker HL, Götze O. Expression and induction of anaphylatoxin C5a receptors in the rat liver. Histol Histopathol. 2003;18:299–308.
35. Schieferdecker HL, Schlaf G, Koleva M, Götze O, Jungermann K. Induction of functional anaphylatoxin C5a receptors on hepatocytes by in vivo treatment of rats with IL-6. J Immunol. 2000;164:5453–8.
36. Chang WJ, Du Y, Zhao X, Ma LY, Cao GW. Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol. 2014;20:4586–96.
37. Murata S, Eguchi Y, Terata N, Tani T, Kodama M. Expression of HLA-DR and urokinase-type plasminogen activator in stage IV gastric cancer. Gastric Cancer. 1998;1:71–7.
38. Beyer BC, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, et al. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer. 2006;106:1026–35.
39. Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system part II: role in immunity. Front Immunol. 2015;6:257.
40. Nitta H, Murakami Y, Wada Y, Eto M, Baba H, Imamura T. Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness. Oncol Rep. 2014;32:1715–9.
41. Nunez-Cruz S, Gimotty PA, Guerra MW, Connolly DC, Wu YQ, DeAngelis RA, et al. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia. 2012;14:994–1004.